

**DRUG PRIOR AUTHORIZATION COMMITTEE**

**March 17, 2016**

**TENTATIVE AGENDA**

Department of Natural Resources  
Lacharette/Nightingale Rooms  
1101 Riverside Drive  
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:10	Minutes Review	Discussion/Approval
10:10 - 10:20	Pharmacy Program/ Budget Update	Steve Calloway/Elizabeth Short
10:20 - 10:25	DUR Update	Steve Calloway

**Old Business**

10:25 – 10:30	<b>A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)</b>	Steve Calloway
---------------	--	----------------

**New Business**

10:30 – 10:35	<b>B. Proposed Actions- New Drug/Product Review</b> (See website and Attached Summary)	Steve Calloway
---------------	---	----------------

- I. Open Access**
- II. Clinical Edit/Step Therapy**
- III. PDL Products**
- IV. Prior Authorization**
  - Discussion
  - Public Hearing
  - Decision

10:35 – 10:55	<b>C. <u>Clinical Edits</u></b> <ul style="list-style-type: none"><li><b>I. Orkambi</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>II. Transmucosal Immediate-Release Fentanyl (TIRF)</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>III. Short-Acting Narcotics</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ul>	
---------------	--	--

**D. Preferred Drug List (PDL)**

- IV. Benzoyl Peroxide/Clindamycin Topical Agents**
  - Discussion
  - Public Hearing
  - Decision
- V. Beta-Adrenergic Agents: Long Acting**
  - Discussion
  - Public Hearing
  - Decision
- VI. Beta-Adrenergic Agents: Nebulized**
  - Discussion
  - Public Hearing
  - Decision
- VII. Beta-Adrenergic Agents: Short Acting**
  - Discussion
  - Public Hearing
  - Decision
- VIII. COPD Anticholinergics**
  - Discussion
  - Public Hearing
  - Decision
- IX. Cough & Cold Agents**
  - Discussion
  - Public Hearing
  - Decision
- X. Herpes Antivirals**
  - Discussion
  - Public Hearing
  - Decision
- XI. Inhaled Antibiotics**
  - Discussion
  - Public Hearing
  - Decision
- XII. Inhaled Corticosteroids**
  - Discussion
  - Public Hearing
  - Decision
- XIII. Intranasal Antihistamines**
  - Discussion
  - Public Hearing
  - Decision

- XIV. Leukotriene Modifiers**
  - Discussion
  - Public Hearing
  - Decision
- XV. Low Sedating Antihistamines**
  - Discussion
  - Public Hearing
  - Decision
- XVI. Low Sedating Antihistamine/Decongestant Combinations**
  - Discussion
  - Public Hearing
  - Decision
- XVII. Nasal Steroids**
  - Discussion
  - Public Hearing
  - Decision
- XVIII. Onychomycosis Antifungals**
  - Discussion
  - Public Hearing
  - Decision
- XIX. Ophthalmic Antihistamines**
  - Discussion
  - Public Hearing
  - Decision
- XX. Ophthalmic Mast Cell Stabilizers**
  - Discussion
  - Public Hearing
  - Decision
- XXI. Ophthalmic NSAIDS**
  - Discussion
  - Public Hearing
  - Decision
- XXII. Ophthalmic Prostaglandin Agonists**
  - Discussion
  - Public Hearing
  - Decision
- XXIII. Ophthalmic Quinolones**
  - Discussion
  - Public Hearing
  - Decision

- XXIV. Otic Quinolones**
  - Discussion
  - Public Hearing
  - Decision
- XXV. Pancreatic Enzymes**
  - Discussion
  - Public Hearing
  - Decision
- XXVI. Self-Injectable Epinephrine Agents**
  - Discussion
  - Public Hearing
  - Decision
- XXVII. Topical Agents for Psoriasis**
  - Discussion
  - Public Hearing
  - Decision
- XXVIII. Topical Androgenic Agents**
  - Discussion
  - Public Hearing
  - Decision
- XXIX. Topical Antifungals**
  - Discussion
  - Public Hearing
  - Decision
- XXX. Topical Antiparasitics**
  - Discussion
  - Public Hearing
  - Decision
- XXXI. Topical Antivirals**
  - Discussion
  - Public Hearing
  - Decision
- XXXII. Topical Immunomodulators**
  - Discussion
  - Public Hearing
  - Decision
- XXXIII. Topical Retinoids**
  - Discussion
  - Public Hearing
  - Decision

**XXXIV. Topical Steroids**

- Discussion
- Public Hearing
- Decision

**XXXV. Ulcerative Colitis Agents – Oral**

- Discussion
- Public Hearing
- Decision

**XXXVI. Ulcerative Colitis Agents - Rectal**

- Discussion
- Public Hearing
- Decision

**E. Preferred Drug List Classes for June/July**

- I. Process Discussion
- II. Therapeutic classes/to be announced at meeting

1:00–1:15

**LUNCH**

1:15-1:30

**F. Program Utilization Information-Xerox Update**

Luke Boehmer

1:30-1:50

**G. Other Business**

- “Top 25” Drugs by Cost/Claims
- Clinical Edit Summary Report
- Call Center Statistics

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly*

**NEXT MEETING: June 16, 2016**

**Department of Natural Resources - 1101 Riverside Dr.**

**Lacharrette/Nightengale Rooms**